Welcome
Good morning and welcome to the first edition of the STAT China newsletter.
My name is Jonathan Chan and I’m writing to you from the bustling city of Hong Kong. Every Tuesday morning — Tuesday night for those of you in my time zone — I will take you through some of the latest health care and biotech developments coming out of China.
What will the newsletter look like? I’ll round up important stories from the past week, adding some analysis and reporting when I can. With China’s health care system going through reforms, I’ll also tell you about policy changes that could have implications for pharma and biotech companies operating here. Along the way, I hope to highlight interesting biotech startups and executives I come across.
A little background on me: Born and raised in Hong Kong, I went to school in Canada and studied biotechnology. I distinctly remember learning about golden rice and thinking “this will revolutionize health care in developing countries.” (It hasn’t.) Since then I’ve been following health care developments in Asia and started focusing on China in the last few years.
So why are we starting a STAT China newsletter? It’s no secret that China represents an important growth market for the global biopharma sector – its health care market is widely estimated to exceed $1 trillion this year. Boasting its own stock exchanges and a number of high-tech industrial parks playing host to homegrown pharma and biotech companies, I think there’s still plenty to learn and discover about this emerging market.
With that in mind, I’d like to invite you to explore this new frontier with me, by sharing your tips, thoughts, or feedback on the newsletter. You can find me at jonathan.chan@statnews.com.
My name is Jonathan Chan and I’m writing to you from the bustling city of Hong Kong. Every Tuesday morning — Tuesday night for those of you in my time zone — I will take you through some of the latest health care and biotech developments coming out of China.
What will the newsletter look like? I’ll round up important stories from the past week, adding some analysis and reporting when I can. With China’s health care system going through reforms, I’ll also tell you about policy changes that could have implications for pharma and biotech companies operating here. Along the way, I hope to highlight interesting biotech startups and executives I come across.
A little background on me: Born and raised in Hong Kong, I went to school in Canada and studied biotechnology. I distinctly remember learning about golden rice and thinking “this will revolutionize health care in developing countries.” (It hasn’t.) Since then I’ve been following health care developments in Asia and started focusing on China in the last few years.
So why are we starting a STAT China newsletter? It’s no secret that China represents an important growth market for the global biopharma sector – its health care market is widely estimated to exceed $1 trillion this year. Boasting its own stock exchanges and a number of high-tech industrial parks playing host to homegrown pharma and biotech companies, I think there’s still plenty to learn and discover about this emerging market.
With that in mind, I’d like to invite you to explore this new frontier with me, by sharing your tips, thoughts, or feedback on the newsletter. You can find me at jonathan.chan@statnews.com.
.png)
No hay comentarios:
Publicar un comentario